XML 56 R37.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment, Geographic and Other Revenue Information (Tables) | 6 Months Ended
--- | ---
Jun. 28, 2020
Segment Reporting [Abstract] |
Reconciliation of Revenue from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 9,795 |  |  | $ | 9,432 |  |  | $ | 6,650 |  |  | $ | 6,071 |
Upjohn |  | 2,006 |  |  | 2,970 |  |  | 1,168 |  |  | 1,973 |
Total reportable segments |  | 11,801 |  |  | 12,402 |  |  | 7,818 |  |  | 8,044 |
Other business activities |  | — |  |  | 862 |  |  | (1,530 | ) |  | (1,193 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (1,136 | ) |  | (1,399 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (910 | ) |  | (1,178 | )
Acquisition-related costs |  | — |  |  | — |  |  | (21 | ) |  | 176 |
Certain significant items(b) |  | — |  |  | — |  |  | (268 | ) |  | (309 | )
|  | $ | 11,801 |  |  | $ | 13,264 |  |  | $ | 3,953 |  |  | $ | 4,141 |
|  | Six Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 19,802 |  |  | $ | 18,477 |  |  | $ | 13,379 |  |  | $ | 11,954 |
Upjohn |  | 4,027 |  |  | 6,184 |  |  | 2,359 |  |  | 4,251 |
Total reportable segments |  | 23,829 |  |  | 24,661 |  |  | 15,738 |  |  | 16,206 |
Other business activities |  | — |  |  | 1,721 |  |  | (3,019 | ) |  | (2,306 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (2,245 | ) |  | (2,676 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (1,722 | ) |  | (2,217 | )
Acquisition-related costs |  | — |  |  | — |  |  | (34 | ) |  | 148 |
Certain significant items(b) |  | — |  |  | — |  |  | (879 | ) |  | (691 | )
|  | $ | 23,829 |  |  | $ | 26,382 |  |  | $ | 7,838 |  |  | $ | 8,463 |
(a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019, and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.
(b) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
The following table provides selected income statement information by reportable segment:
|  | Three Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 9,795 |  |  | $ | 9,432 |  |  | $ | 6,650 |  |  | $ | 6,071 |
Upjohn |  | 2,006 |  |  | 2,970 |  |  | 1,168 |  |  | 1,973 |
Total reportable segments |  | 11,801 |  |  | 12,402 |  |  | 7,818 |  |  | 8,044 |
Other business activities |  | — |  |  | 862 |  |  | (1,530 | ) |  | (1,193 | )
Reconciling Items: |  |  |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (1,136 | ) |  | (1,399 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (910 | ) |  | (1,178 | )
Acquisition-related costs |  | — |  |  | — |  |  | (21 | ) |  | 176 |
Certain significant items(b) |  | — |  |  | — |  |  | (268 | ) |  | (309 | )
|  | $ | 11,801 |  |  | $ | 13,264 |  |  | $ | 3,953 |  |  | $ | 4,141 |
|  | Six Months Ended
|  | Revenues |  | Earnings(a)
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Reportable Segments: |  |  |  |  |  |  |  |
Biopharma |  | $ | 19,802 |  |  | $ | 18,477 |  |  | $ | 13,379 |  |  | $ | 11,954 |
Upjohn |  | 4,027 |  |  | 6,184 |  |  | 2,359 |  |  | 4,251 |
Total reportable segments |  | 23,829 |  |  | 24,661 |  |  | 15,738 |  |  | 16,206 |
Other business activities |  | — |  |  | 1,721 |  |  | (3,019 | ) |  | (2,306 | )
Reconciling Items: |  |  |  |  |  |  |  |
Corporate and other unallocated |  | — |  |  | — |  |  | (2,245 | ) |  | (2,676 | )
Purchase accounting adjustments |  | — |  |  | — |  |  | (1,722 | ) |  | (2,217 | )
Acquisition-related costs |  | — |  |  | — |  |  | (34 | ) |  | 148 |
Certain significant items(b) |  | — |  |  | — |  |  | (879 | ) |  | (691 | )
|  | $ | 23,829 |  |  | $ | 26,382 |  |  | $ | 7,838 |  |  | $ | 8,463 |
(a) | Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include d ividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019, and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.
(b) | Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.
Schedule of Revenues by Geographic Region |
The following table provides revenues by geographic area:
|  | Three Months Ended |  | Six Months Ended
(MILLIONS OF DOLLARS) |  | June 28, 2020 |  |  | June 30, 2019 |  |  | % Change |  |  | June 28, 2020 |  |  | June 30, 2019 |  |  | % Change |
United States |  | $ | 5,402 |  |  | $ | 6,335 |  |  | (15 | ) |  | $ | 11,053 |  |  | $ | 12,510 |  |  | (12 | )
Developed Europe(a) |  | 2,088 |  |  | 2,228 |  |  | (6 | ) |  | 4,009 |  |  | 4,315 |  |  | (7 | )
Developed Rest of World(b) |  | 1,552 |  |  | 1,639 |  |  | (5 | ) |  | 3,008 |  |  | 3,174 |  |  | (5 | )
Emerging Markets(c) |  | 2,759 |  |  | 3,062 |  |  | (10 | ) |  | 5,759 |  |  | 6,383 |  |  | (10 | )
Revenues |  | $ | 11,801 |  |  | $ | 13,264 |  |  | (11 | ) |  | $ | 23,829 |  |  | $ | 26,382 |  |  | (10 | )
(a) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in the second quarter of 2020 and $1.8 billion in the second quarter of 2019, and were $3.2 billion in the first six months of 2020 and $3.5 billion in the first six months of 2019.
(b) | Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
(c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
Schedule of Significant Product Revenues | The following table provides detailed revenue information for several of our major products:
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Six Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
TOTAL REVENUES |  |  |  | $ | 11,801 |  |  | $ | 13,264 |  |  | $ | 23,829 |  |  | $ | 26,382 |
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA) |  | $ | 9,795 |  |  | $ | 9,432 |  |  | $ | 19,802 |  |  | $ | 18,477 |
Internal Medicine(a) |  |  |  | $ | 2,279 |  |  | $ | 2,243 |  |  | $ | 4,610 |  |  | $ | 4,380 |
Eliquis alliance revenues and direct sales |  | Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism |  | 1,272 |  |  | 1,085 |  |  | 2,572 |  |  | 2,096 |
Chantix/Champix |  | An aid to smoking cessation treatment in adults 18 years of age or older |  | 235 |  |  | 276 |  |  | 505 |  |  | 549 |
Premarin family |  | Symptoms of menopause |  | 152 |  |  | 193 |  |  | 304 |  |  | 361 |
BMP2 |  | Development of bone and cartilage |  | 57 |  |  | 79 |  |  | 127 |  |  | 145 |
Toviaz |  | Overactive bladder |  | 64 |  |  | 65 |  |  | 124 |  |  | 125 |
All other Internal Medicine |  | Various |  | 498 |  |  | 544 |  |  | 978 |  |  | 1,103 |
Oncology |  |  |  | $ | 2,647 |  |  | $ | 2,236 |  |  | $ | 5,082 |  |  | $ | 4,198 |
Ibrance |  | Metastatic breast cancer |  | 1,349 |  |  | 1,261 |  |  | 2,598 |  |  | 2,394 |
Xtandi alliance revenues |  | Non-metastatic and metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer |  | 266 |  |  | 201 |  |  | 475 |  |  | 369 |
Sutent |  | Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor |  | 209 |  |  | 248 |  |  | 414 |  |  | 480 |
Inlyta |  | Advanced RCC |  | 195 |  |  | 104 |  |  | 364 |  |  | 177 |
Xalkori |  | ALK-positive and ROS1-positive advanced NSCLC |  | 138 |  |  | 133 |  |  | 287 |  |  | 255 |
Bosulif |  | Philadelphia chromosome–positive chronic myelogenous leukemia |  | 113 |  |  | 97 |  |  | 213 |  |  | 177 |
Retacrit(b) |  | Anemia |  | 87 |  |  | 51 |  |  | 176 |  |  | 82 |
Braftovi |  | In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAF V600E-mutant metastatic colorectal cancer after prior therapy |  | 36 |  |  | — |  |  | 74 |  |  | — |
Mektovi |  | In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation |  | 32 |  |  | — |  |  | 69 |  |  | — |
All other Oncology |  | Various |  | 221 |  |  | 140 |  |  | 412 |  |  | 262 |
Hospital(a), (c) |  |  |  | $ | 1,794 |  |  | $ | 1,838 |  |  | $ | 3,807 |  |  | $ | 3,665 |
Sulperazon |  | Bacterial infections |  | 102 |  |  | 165 |  |  | 289 |  |  | 342 |
Medrol |  | Anti-inflammatory glucocorticoid |  | 78 |  |  | 120 |  |  | 207 |  |  | 240 |
Zithromax |  | Bacterial infections |  | 55 |  |  | 73 |  |  | 193 |  |  | 177 |
Precedex |  | Sedation agent in surgery or intensive care |  | 114 |  |  | 40 |  |  | 156 |  |  | 80 |
Vfend |  | Fungal infections |  | 75 |  |  | 94 |  |  | 149 |  |  | 178 |
Panzyga |  | Primary humoral immunodeficiency |  | 63 |  |  | 44 |  |  | 136 |  |  | 61 |
(MILLIONS OF DOLLARS) |  |  |  | Three Months Ended |  | Six Months Ended
PRODUCT |  | PRIMARY INDICATION OR CLASS |  | June 28, 2020 |  |  | June 30, 2019 |  |  | June 28, 2020 |  |  | June 30, 2019 |
Zyvox |  | Bacterial infections |  | 55 |  |  | 71 |  |  | 125 |  |  | 134 |
Fragmin |  | Treatment/prevention of venous thromboembolism |  | 58 |  |  | 63 |  |  | 118 |  |  | 123 |
Pfizer CentreOne(d) |  | Various |  | 224 |  |  | 204 |  |  | 376 |  |  | 380 |
All other Anti-infectives |  | Various |  | 367 |  |  | 420 |  |  | 811 |  |  | 825 |
All other Hospital(c) |  | Various |  | 603 |  |  | 544 |  |  | 1,245 |  |  | 1,124 |
Vaccines |  |  |  | $ | 1,247 |  |  | $ | 1,375 |  |  | $ | 2,857 |  |  | $ | 2,988 |
Prevnar 13/Prevenar 13 |  | Pneumococcal disease |  | 1,116 |  |  | 1,179 |  |  | 2,566 |  |  | 2,665 |
Nimenrix |  | Meningococcal disease |  | 56 |  |  | 58 |  |  | 130 |  |  | 107 |
All other Vaccines |  | Various |  | 75 |  |  | 138 |  |  | 161 |  |  | 215 |
Inflammation & Immunology (I&I) |  | $ | 1,149 |  |  | $ | 1,219 |  |  | $ | 2,127 |  |  | $ | 2,256 |
Xeljanz |  | RA, PsA, UC |  | 635 |  |  | 613 |  |  | 1,086 |  |  | 1,036 |
Enbrel (Outside the U.S. and Canada) |  | RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis |  | 337 |  |  | 420 |  |  | 684 |  |  | 871 |
Inflectra/Remsima(b) |  | Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis |  | 150 |  |  | 153 |  |  | 308 |  |  | 291 |
All other I&I |  | Various |  | 26 |  |  | 34 |  |  | 48 |  |  | 59 |
Rare Disease |  |  |  | $ | 681 |  |  | $ | 521 |  |  | $ | 1,319 |  |  | $ | 991 |
Vyndaqel/Vyndamax |  | ATTR-cardiomyopathy and polyneuropathy |  | 277 |  |  | 63 |  |  | 508 |  |  | 104 |
BeneFIX |  | Hemophilia B |  | 109 |  |  | 121 |  |  | 230 |  |  | 247 |
Genotropin |  | Replacement of human growth hormone |  | 106 |  |  | 125 |  |  | 209 |  |  | 232 |
Refacto AF/Xyntha |  | Hemophilia A |  | 91 |  |  | 108 |  |  | 181 |  |  | 214 |
Somavert |  | Acromegaly |  | 67 |  |  | 68 |  |  | 131 |  |  | 128 |
All other Rare Disease |  | Various |  | 31 |  |  | 35 |  |  | 61 |  |  | 66 |
UPJOHN(a) |  |  |  | $ | 2,006 |  |  | $ | 2,970 |  |  | $ | 4,027 |  |  | $ | 6,184 |
Lipitor |  | Reduction of LDL cholesterol |  | 431 |  |  | 407 |  |  | 836 |  |  | 1,029 |
Lyrica |  | Epilepsy, post-herpetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury |  | 349 |  |  | 1,175 |  |  | 706 |  |  | 2,362 |
Norvasc |  | Hypertension |  | 222 |  |  | 216 |  |  | 419 |  |  | 516 |
Celebrex |  | Arthritis pain and inflammation, acute pain |  | 139 |  |  | 174 |  |  | 295 |  |  | 347 |
Viagra |  | Erectile dysfunction |  | 94 |  |  | 114 |  |  | 222 |  |  | 259 |
Effexor |  | Depression and certain anxiety disorders |  | 86 |  |  | 86 |  |  | 163 |  |  | 163 |
Zoloft |  | Depression and certain anxiety disorders |  | 79 |  |  | 73 |  |  | 157 |  |  | 143 |
EpiPen(a) |  | Epinephrine injection used in treatment of life-threatening allergic reactions |  | 64 |  |  | 67 |  |  | 136 |  |  | 123 |
Xalatan/Xalacom |  | Glaucoma and ocular hypertension |  | 65 |  |  | 72 |  |  | 126 |  |  | 133 |
All other Upjohn |  | Various |  | 476 |  |  | 587 |  |  | 968 |  |  | 1,109 |
CONSUMER HEALTHCARE BUSINESS(e) |  | $ | — |  |  | $ | 862 |  |  | $ | — |  |  | $ | 1,721 |
Total Alliance revenues |  |  |  | $ | 1,404 |  |  | $ | 1,187 |  |  | $ | 2,786 |  |  | $ | 2,277 |
Total Biosimilars(b) |  |  |  | $ | 289 |  |  | $ | 217 |  |  | $ | 578 |  |  | $ | 396 |
Total Sterile Injectable Pharmaceuticals(f) |  | $ | 1,237 |  |  | $ | 1,218 |  |  | $ | 2,644 |  |  | $ | 2,455 |
(a) | Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
(b) | Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
(c) | Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
(d) | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
(e) | On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.
(f) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration